2011
DOI: 10.1016/j.ejmech.2011.01.001
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and evaluation of aroylthiourea derivatives of 4-β-amino-4'-O-demethyl-4-desoxypodophyllotoxin as novel topoisomerase II inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
11
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 33 publications
(11 citation statements)
references
References 19 publications
0
11
0
Order By: Relevance
“…Many reports in recent years have indicated that inhibitory action towards Topo II coincides with cytotoxic properties for several naturally occurring and synthetic compounds [2530]. We therefore subjected 1 to a preliminary MTT assay in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells to identify any possible correlation.…”
Section: Resultsmentioning
confidence: 99%
“…Many reports in recent years have indicated that inhibitory action towards Topo II coincides with cytotoxic properties for several naturally occurring and synthetic compounds [2530]. We therefore subjected 1 to a preliminary MTT assay in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells to identify any possible correlation.…”
Section: Resultsmentioning
confidence: 99%
“…Several complexes, including thiourea-platinum [18] , -gold [19] , -iron [20] , and -copper [21] , have been synthesized. Thiourea derivatives of classic anticancer drugs such as camptothecin [22] and podophyllum [23] have also been synthesized and tested for the anticancer activities. In recent years, the successful development of target-specific compounds received widespread recognition for their utility in clinical treatment.…”
Section: Discussionmentioning
confidence: 99%
“…To overcome these disadvantages, extensive derivation efforts have been continuously carried out in many research laboratories all over the world. As it was found that the sugar moiety of etoposide was not essential for topoisomerase II inhibition (Ren, Wu, Xin, Chen, & Hu, ; Zhao et al., ), several potential C4‐non‐sugar substituted derivatives of 4′‐demethyl‐PPT (Kamal, Ashwini Kumar, Suresh, Juvekar, & Zingde, ; Kumar et al., ; Li et al., ; Sun et al., ; Tang et al., ; Zhang, Chen, Zhang, Chen, & Wang, ; Zhang et al., ) such as GL‐331 ( 4 ) (Huang et al., ; Lee, ), NK‐611 (Utsugi et al., ), NPF, and TOP‐53 ( 5 ) were brought into human clinical trials. However, they did not proceed further (Mross et al., ).…”
Section: Introductionmentioning
confidence: 99%